Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Blood

Volumn 116, Issue 22, 2010, Pages 4560-4568

  Hoang, Bao ^a   Frost, Patrick ^a   Shi, Yijiang ^a   Belanger, Eileen ^a   Benavides, Angelica ^a   Pezeshkpour, Gholam ^b   Cappia, Susanna ^c   Guglielmelli, Tommasina ^c   Gera, Joseph ^a   Lichtenstein, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PP 242; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; S6 KINASE; SERINE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 78649471733     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-285726     Document Type: Article

References (37)

1. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62(17):5027-5034.
2. Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103(9):3138-3147.
3. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004;104(12):4188-4193.
4. Guertin D, Sabatini D. The Pharmacology of mTOR inhibition. Sciencesignaling. 2009;2(67):1-6.
5. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(6):1926-1945.
6. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433(4):477-480.
7. Kim DH, Sabatini DM. Raptor and mTOR:subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol. 2004;279(2):259-270.
8. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol. 2004;279(4):339-359.
9. Raje N, Richardson P, Hari PN, et al. An open label phase I study of the safety and efficacy of RAD001 in combination with lenalidomide in the treatment of patients with relapsed and refractory multiple myeloma [abstract]. Blood. 2009;114:1483.
10. Ghobrial I, Munshi N, Schlossman R, et al. Phase I trial of CCI-779 (Temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma [abstract]. Blood. 2008;112:1266.
11. Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res. 2009;33(6):1475-1480.
12. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. MTOR inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the IGF receptor/ IRS-1/PI3-kinase cascade. Mol Cancer Ther. 2005;4(10):1533-1540.
13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science. 2005;307(8):1098- 1101.
14. Hresko RC, Mueckler M. mTOR-RICTOR is the ser473 kinase for AKT/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280(54):40406-40416.
15. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853-2855.
16. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 20009;7(2):371-382.
17. Frost P, Shi Y, Hoang B, Gera J, Lichtenstein A. Regulation of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther. 2009;8(1):83-93.
18. Sharma S, Lichtenstein A. Dexamethasone-nduced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood. 2008;112(4):1338-1345.
19. Sharma S, Nemeth E, Chen Y, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262-3267.
20. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104(13):4181-4187.
21. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mTOR: Phospho-Ser 2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009;69(6):1821-1827.
22. Murray JT, Campbell DG, Morrice N, et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and SGK3. Biochem J. 2004;384(5):477-488.
23. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of TORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-3074.
24. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits TORC2 assembly and AKT. Molec. Cell. 2006;22(1):159-168.
25. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999;13(4):1422-1437.
26. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translational inhibitor 4E-BP1. Genes Dev. 2001;15(8):2852-2864.
27. Mothe-Satney I, Brunn GJ, McMahon LP, et al. MTOR-dependent phosphorylation of PHAS-1 in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem. 2000;275(26):33836-33843.
28. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 2010;16(1):205-213.
29. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2006;30(2):262-265.
30. Chng WJ, Gonzalez-Paz N, Price-Troska, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22(7):2280-2284.
31. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(1):1-14.
32. Zollinger A, Stuhmer T, Chatterjee M, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: AKT-dependent and AKT-independent multiple myeloma. Blood. 2008;112(8):3403- 3411.
33. Dehner M, Hadjihannas M, Weiske J, Huber O, Behrens J. Wnt signaling inhibits forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1. J Biol Chem. 2008;283(28):19201-19210.
34. Yan L, Mieulet V, Lamb RF. mTORC2 is the hydrophobic motif kinase for SGK1. Biochem J. 2008;416:e19-21.
35. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(3):1296-1302.
36. Ng T, Shima D, Squire A, et al. PKCα regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J. 1999;18(14):3909-3923.
37. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and PI3-kinase/AKT signaling. Cancer Res. 2003;63(21):7543-7550.